prescription spending high-cost specialty drugs genetic and metabolic markers Related: FDA fast-tracking gene therapies A prescription for wasteful spending
Using metabolic fingerprints to target medication therapy
Real world impact of pharmacogenetics testing
Journal of Medical Economics
Jennifer Fuhrmann-Berger, Pharm.D., is senior vice president of clinical services at BeneCard PBF, a pharmacy benefit manager (PBM) based in Mechanicsburg, Pennsylvania.NOT FOR REPRINT
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.